The African Union is backing calls for drugmakers to waive some intellectual property rights on COVID-19 medicines and vaccines to speed up their rollout to poor countries, the head of its disease control body said on Thursday.
South Africa and India, which both manufacture drugs and vaccines, made the proposal at the World Trade Organization (WTO) last year, arguing that intellectual property (IP) rules were hindering the urgent scale-up of vaccine production and provision of medical products to some patients.
They have faced opposition from some developed nations, but the backing of the African Union (AU) may give renewed impetus for the push to relax IP rules.
John Nkengasong, director of the Africa Centers for Disease Control and Prevention, told a news conference that IP transfer was a “win-win for everybody” that would address the huge inequalities in global public health.
He gave two examples where the developing world had suffered because of restricted access to medicines: the swine flu pandemic in the late 2000s and HIV/AIDS in the 1990s.
“In 1996, HIV drugs were available, and we saw how mortality in the developed world decreased drastically. But it would take 10 years before those drugs were accessible in Africa in any meaningful way,” he said.
“In between, 12 million Africans died, so I just use those numbers to say: any IP transfer will be beneficial to everybody because nobody wants to sit back and be proud of that sad event … We want to be on the right side of history.”
He said the developers of Russia’s Sputnik V vaccine had submitted a “full dossier” of data to the Africa CDC and that in the coming days an expert panel would review the data and make a pronouncement.
“We have not received dossiers yet from China colleagues, but we remain optimistic that they will submit to us,” he continued.
Several countries on the continent, including Egypt, Zimbabwe, and Senegal, have already started rolling out Chinese COVID-19 shots.
Follow our socials Whatsapp, Facebook, Instagram, Twitter, and Google News.
